Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10012464 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL866170 | 0.79 | TSHR (0.50) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL5864497 | 0.79 | TSHR (0.50) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL10017663 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL13741176 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL13741138 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL4453532 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL22356006 | 0.77 | CA14 (0.43) | SMN1; SMN2CA14CA12ALDH1A1TSHR | |
| SCHEMBL22356151 | 0.77 | CA14 (0.43) | SMN1; SMN2CA14CA12ALDH1A1TSHR | |
| SCHEMBL4446060 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2CA14CA12ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629494-B2 | Process for producing cyclopropylphenol derivative | MITSUI CHEMICALS AGRO, INC. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20090054681-A1 | Production Process of cyclopropylphenol derivatives | SANKYO AGRO COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1880987-A1 | PROCESS FOR PRODUCING CYCLOPROPYLPHENOL DERIVATIVE | Sankyo Agro Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054681-A1 | Production Process of cyclopropylphenol derivatives | CBR3, CYP4X1, CYP4A11 | SMN1; SMN2 4833/4885CA14 1748/4885CA12 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.